MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

Home・Akcijų sąrašas・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Uždarymo kaina

5.37 4.88

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.89

Max

5.57

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-8.5M -35M
Darbuotojai	166
EBITDA	-11M -37M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+48.38% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-12

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	27M 191M
Ankstesnė atidarymo kaina	0.49
Ankstesnė uždarymo kaina	5.37

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

1.23 / 1.45 Palaikymas ir pasipriešinimas

Zentalis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-14 23:36; UTC

Įsigijimai, susijungimai, perėmimai

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

2026-04-14 23:24; UTC

Karštos akcijos

Stocks to Watch: Gloo, Broadcom, GitLab

2026-04-14 22:42; UTC

Įsigijimai, susijungimai, perėmimai

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

2026-04-14 21:32; UTC

Pagrindinės rinkos jėgos

GitLab Shares Rise on Expanded Google Cloud Collaboration

2026-04-14 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

2026-04-14 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026-04-14 22:54; UTC

Uždarbis

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Targets Deal Completion Toward End of 3Q

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

2026-04-14 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

2026-04-14 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

2026-04-14 22:14; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

2026-04-14 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

2026-04-14 22:12; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

2026-04-14 22:12; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

2026-04-14 22:10; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

2026-04-14 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-04-14 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026-04-14 20:32; UTC

Karštos akcijos

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

2026-04-14 19:59; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026-04-14 19:38; UTC

Uždarbis

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026-04-14 19:27; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

2026-04-14 19:21; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-04-14 19:09; UTC

Įsigijimai, susijungimai, perėmimai

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

2026-04-14 18:30; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-14 18:30; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Akcijų palyginimas

Kainos pokytis

Zentalis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

48.38% į viršų

12 mėnesių prognozė

Vidutinis 8.25 USD 48.38%

Aukščiausias 10 USD

Žemiausias 4 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zentalis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Zentalis Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.23 / 1.45Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.